Psilocybin, a psychedelic compound found in mushrooms, is already known for its potential in treatment-resistant depression. In a more recent study, scientists found that psilocin, the active metabolite of psilocybin, prolonged the lifespan of human skin and lung cells by over 50%. In aged mice, psilocybin treatment also increased survival by 30% over a 10-month period and improved physical signs of aging, including healthier fur, reduced greying, and hair regrowth. The compound appears to reduce oxidative stress, support DNA repair, and preserve telomere length—key markers linked to aging and age-related disease. Notably, these benefits were seen even when treatment began later in life. Together, the findings position psilocybin as a promising geroprotective agent with systemic benefits that extend beyond the brain, potentially offering new paths toward therapies that not only extend life but also promote healthier aging. ⁷

References

1. Quaade AS, et al. Contact Dermatitis. 2021;84:361–374. 2. Grant L, et al. Adv Ther. 2020;37(2):692-706. 3. Dalgard FJ, et al. J Invest Dermatol. 2015;135(4):984-991. 4. Cortesi PA, et al. Contact Dermatitis. 2014;70(3):158-168.5. Bissonnette R, et al. Lancet. 2024;404:461-473. 6. NCT06004050. ClinicalTrials.gov. Accessible from: https://clinicaltrials.gov/study/NCT06004050. 7. Kato K, et al. NPJ Aging. 2025;11(1):55. 8. Hirano KI, Higashi M, Nakajima K. Eur Heart J. 2023 Apr 1;44(13):1191. 9. Qi J, et al. Nat Med. Published online July 2, 2025. doi:10.1038/s41591-025-03773-w. 10. Pryor JL, et al. J Strength Cond Res. 2024;38(7):1350-1357.